Brokerages Set Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Target Price at $44.00

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has been assigned an average rating of “Hold” from the nineteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $44.00.

FMS has been the topic of several research analyst reports. BNP Paribas cut shares of Fresenius Medical Care AG & Co. KGaA from an “outperform” rating to a “neutral” rating in a research report on Thursday, February 4th. Berenberg Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, March 2nd. Nord/LB reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, January 6th. Kepler Capital Markets cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research report on Thursday, February 4th. Finally, Exane BNP Paribas cut shares of Fresenius Medical Care AG & Co. KGaA from an “outperform” rating to a “neutral” rating in a report on Thursday, February 4th.

Shares of NYSE FMS traded up $0.10 during trading on Monday, hitting $37.15. The company had a trading volume of 254,362 shares, compared to its average volume of 479,678. The company has a market cap of $21.76 billion, a P/E ratio of 14.74, a PEG ratio of 1.81 and a beta of 1.21. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $33.32 and a 52 week high of $46.55. The business’s 50-day moving average is $36.12 and its 200 day moving average is $39.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.84 and a current ratio of 1.11.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Tuesday, February 23rd. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.06. Fresenius Medical Care AG & Co. KGaA had a net margin of 7.38% and a return on equity of 10.62%. The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.76 billion. On average, research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.85 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. First Trust Advisors LP bought a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth $54,044,000. Todd Asset Management LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 18.0% in the fourth quarter. Todd Asset Management LLC now owns 511,088 shares of the company’s stock worth $21,240,000 after purchasing an additional 77,799 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth $19,909,000. Teachers Retirement System of The State of Kentucky boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 24.8% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 336,900 shares of the company’s stock worth $14,001,000 after purchasing an additional 66,900 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth $2,894,000. Institutional investors and hedge funds own 1.60% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: What Factors Can Affect Return on Equity?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.